128940 — Hanmi Pharm Co Income Statement
0.000.00%
- KR₩3tn
- KR₩3tn
- KR₩1tn
- 64
- 26
- 26
- 30
Annual income statement for Hanmi Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,075,854 | 1,203,186 | 1,331,547 | 1,490,887 | 1,495,502 |
Cost of Revenue | |||||
Gross Profit | 580,918 | 632,752 | 718,553 | 829,249 | 817,037 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,026,405 | 1,078,723 | 1,178,204 | 1,276,187 | 1,281,798 |
Operating Profit | 49,449 | 124,462 | 153,343 | 214,701 | 213,703 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 22,130 | 103,697 | 121,013 | 193,967 | 171,254 |
Provision for Income Taxes | |||||
Net Income After Taxes | 17,290 | 81,478 | 101,558 | 165,366 | 140,431 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 11,959 | 67,025 | 82,792 | 146,231 | 121,315 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 11,959 | 67,025 | 82,792 | 146,231 | 121,315 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 929 | 5,394 | 6,801 | 11,806 | 9,726 |
Dividends per Share |